Phase II and Phase III clinical trials in South Korea must meet guidelines set by the Ministry of Food and Drug Safety (MFDS). Sponsors must submit detailed trial protocols, ensuring safety, efficacy, and ethical compliance. Good Clinical Practice (GCP) standards apply, with Phase II focusing on dosing and efficacy, and Phase III confirming broader effectiveness and safety.
